Assessment of obsessive-compulsive disorder comorbidity and obsessive-compulsive symptom dimensions in patients with schizophrenia

Kokurcan, Ahmet; Şafak, Yasir

doi:10.15537/smj.2020.3.24909

Cited by 6 publications

(5 citation statements)

References 32 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As regard gender, in the present study 52% of patients were male and 48% were females. This finding is in line with the study by Kruger et al, [8] but in contrast to the study by and Kokurcan and Safak [9] in which there was preponderance of men.…”

Section: Discussionsupporting

confidence: 91%

Socio-demographic Characteristics of Schizo-obsessive Patients

Hameed

Mahmoud

Hassan

et al. 2023

Minia Journal of Medical Research

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Socio-demographic Characteristics of Schizo-obsessive Patients

Hameed

Mahmoud

Hassan

et al. 2023

Minia Journal of Medical Research

View full text Add to dashboard Cite

show abstract

“…[3][4][5] Despite the relatively low prevalence, schizophrenia is associated with substantial health, societal, and economic burden, including high healthcare resource utilization [6][7][8] and increased risk of premature mortality, disability, mental health comorbidities, and suicide. [9][10][11][12][13][14][15] Furthermore, the difficult symptoms associated with schizophrenia profoundly decrease patients' quality of life and daily functioning. 16,17 As a result of confirmed cases of illness caused by a SARS-CoV-2 Novel Coronavirus (2019-nCoV or COVID- 19), the US Secretary of Health and Human Services determined the existence of a public health emergency on January 27, 2020.…”

Section: Introductionmentioning

confidence: 99%

Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey

Zhdanava¹,

Starr²,

Totev³

et al. 2022

NDT

View full text Add to dashboard Cite

Purpose To describe changes due to the COVID-19 pandemic in the prescribing of long-acting antipsychotics (LAI) for schizophrenia, patient outcomes, and patient and healthcare provider (HCP) attitudes regarding COVID-19 vaccination in the United States (US). Methods An anonymous online survey was administered to US-based LAI prescribers with a psychiatry specialty in May 2021. Information on prescriber and clinical practice characteristics, LAI prescribing, patient outcomes, and attitudes toward COVID-19 vaccination was collected and described. Results Of the 401 LAI prescribers meeting survey criteria, 64.6% reported that LAI prescribing remained unchanged (increase: 19.2%, decrease: 14.0%). The majority did not switch patients from LAIs to oral antipsychotics (OAP; 63.3%) or to LAI formulations with lower frequency of administration (68.1%); most prescribers switched the same number of patients from OAPs to LAIs during the pandemic as in previous practice (65.1%). Half of LAI prescribers (50.1%) reported antipsychotic adherence as unchanged among most patients; 44.6% reported symptom control/relapse frequency as unchanged. Most prescribers believed their patients with schizophrenia should be prioritized for COVID-19 vaccination (74.1%) and encouraged all patients to obtain a COVID-19 vaccine (84.0%). However, 64.1% of prescribers reported hesitancy among some patients about vaccines’ safety; 51.4% reported that some patients were willing to be vaccinated despite the hesitancy, 48.6% indicated that some patients perceived COVID-19 vaccines as safe, effective, and important. Conclusion LAI prescribing and prescriber-reported antipsychotic adherence in patients with schizophrenia remained largely unchanged approximately one year after the start of COVID-19. Focused efforts to overcome patients’ COVID-19 vaccine hesitancy are warranted.

show abstract

“…It was reported that the first psychotic symptoms started earlier in the schizo-obsessive group when compared with schizo-obsessive patients and another group of patients with schizophrenia who did not have appropriate OCS in terms of age, sex, and hospitalization (O'Connell et al, 2018). In addition, there was no difference between schizo-obsessive patients and patients with schizophrenia without OCS/OCD in terms of positive, negative, and disorganized schizophrenia symptoms (Kokurcan and Şafak, 2020). Again, in a study comparing the schizo-obsessive patient group and the OCD patient group in terms of clinical and demographic characteristics, it was shown that there was no difference between the two groups in terms of the frequency and severity of OCS (Kazhungil et al, 2017).…”

mentioning

confidence: 96%

Comparative Clinical and Neuropsychological Characteristics in Schizophrenia and Schizophrenia–Obsessive-Compulsive Disorder Patients

Temircan¹,

Demirtaş

2021

J Nerv Ment Dis

View full text Add to dashboard Cite

The present study aimed to compare neuropsychological characteristics of patients with schizophrenia and patients with schizophrenia-obsessive-compulsive disorder (OCD). A total of 78 patients were included in the study, with 32 patients diagnosed with schizophrenia and 46 patients diagnosed with schizophrenia-OCD according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria. Two groups of the patients were compared with each other in terms of demographic data, psychotic symptoms, and clinical and neuropsychological characteristics. In this study, the schizophrenia-OCD relationship was seen at a higher rate in male patients, and this group has worse clinical features. In addition, there was no significant difference among sociodemographics, clinical characteristics, and social and neuropsychological functionality between the two groups. According to our results, patients with schizophrenia-OCD experience more depression and anxiety that are related to poorer quality of life. Longitudinal and more homogeneous patient groups are needed for further studies to reveal whether schizophrenia accompanied by OCD is a comorbidity, a subtype of schizophrenia, or a different disorder.

show abstract

Assessment of obsessive-compulsive disorder comorbidity and obsessive-compulsive symptom dimensions in patients with schizophrenia

Abstract: To assess obsessive-compulsive disorder (OCD) comorbidity and obsessive-compulsive symptom (OCS) dimensions in patients with schizophrenia. Methods: This cross-sectional study included 300 patients with schizophrenia who were applied to the to the

Cited by 6 publications

References 32 publications

Socio-demographic Characteristics of Schizo-obsessive Patients

Socio-demographic Characteristics of Schizo-obsessive Patients

Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey

Comparative Clinical and Neuropsychological Characteristics in Schizophrenia and Schizophrenia–Obsessive-Compulsive Disorder Patients

Contact Info

Product

Resources

About